Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)-Reference-Cited by-同舟云学术

Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Published:2023-01-05 Issue:8 Volume:108 Page:2244-2248
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Rummelt Christoph,Grishina Olga,Schmoor Claudia,Crysandt Martina,Heuser Michael,Götze Katharina S.,Schlenk Richard F.,Döhner Konstanze,Salih Helmut R.,Heil Gerhard,Müller-Tidow Carsten,Brugger Wolfram,Kündgen Andrea,De Wit Maike,Giagounidis Aristoteles,Scholl Sebastian,Neubauer Andreas,Krauter Jürgen,Bug Gesine,Al-Ali Haifa Kathrin,Wäsch Ralph,Becker Heiko,May Annette M.,Duyster Justus,Hackanson Björn,Ganser Arnold,Döhner Hartmut,Lübbert Michael

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference16 articles.

1. Silverman LR., Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429-2440.

2. Kantarjian H, Issa JPJ, Rosenfeld CS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106(8):1794-1803.

3. Lübbert M, Suciu S, Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011; 29(15):1987-1996.

4. Zeidan AM, Davidoff AJ, Long JB. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016; 175(5):829-840.

5. Maakaron J.E. Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. Ann. Hematol. 2020; 99:1411-1413.